Cabozantinib for previously treated radioiodine‐refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC‐311 trial
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34493
Abstract: At an interim analysis (median follow‐up, 6.2 months; n = 187), the phase 3 COSMIC‐311 trial met the primary end point of progression‐free survival (PFS): cabozantinib improved PFS versus a placebo (median, not reached vs.… read more here.
Keywords: previously treated; cosmic 311; treated radioiodine; 311 trial ... See more keywords
Estimated Dose to Family Members of Patients Treated with Radioiodine
Sign Up to like & getrecommendations! Published in 2017 at "Radiation Protection Dosimetry"
DOI: 10.1093/rpd/ncw138
Abstract: Patients who receive therapeutic amount of 131I are potentially significant source of radiation to their family members and general public. The aim of this study was to estimate effective dose to family members of patients… read more here.
Keywords: patients treated; dose family; members patients; family members ... See more keywords